Alphabet soup: a personal, evolving, mostly evidence-based and logical, sequential approach to the "ABCNR" drugs in multiple sclerosis.
With the development of multiple options for immunotherapy in multiple sclerosis, the clinician is faced with the challenge of keeping pace with the literature, acquiring familiarity with the various treatment options and opinions, and then offering the patients the most current and appropriate management. Given the inherent nature of a multifocal and unpredictable disease such as multiple sclerosis, along with the availability of multiple treatment options, it behooves the clinician to develop an evidence-based rationale for how to best manage patients. This article reflects the common questions that arise from referring neurologists regarding my personal approach to the management of patients with multiple sclerosis.
Mattson
David H
DH
Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000465:Algorithms; D019090:Case Management; D004341:Drug Evaluation; D019317:Evidence-Based Medicine; D000068717:Glatiramer Acetate; D006801:Humans; D007167:Immunotherapy; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000009:adverse effects / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D008942:Mitoxantrone / Q000009:adverse effects / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000145:classification / Q000188:drug therapy* / Q000473:pathology; D010455:Peptides / Q000009:adverse effects / Q000627:therapeutic use; D011379:Prognosis; D012074:Remission Induction; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D010455:Peptides; D000068576:Interferon beta-1b; D000068717:Glatiramer Acetate; D016899:Interferon-beta; D008942:Mitoxantrone; D000068556:Interferon beta-1a